Skip to main content
Top
Published in: Pituitary 6/2020

01-12-2020 | Pituitary Adenoma

Treatment of sellar metastases with gamma knife radiosurgery in patients with advanced cancer

Authors: Carolina Benjamin, Kimberly Ashayeri, John G. Golfinos, Dimitris G. Placantonakis, Joshua Silverman, Douglas Kondziolka

Published in: Pituitary | Issue 6/2020

Login to get access

Abstract

Purpose

Metastases should be considered in a patient with a cancer history and a sellar/suprasellar lesion, as this diagnosis can change the management strategy in such patients. Once the diagnosis is established, stereotactic radiosurgery (SRS) can be a safe and effective approach for these patients.

Methods

This case series describes five patients with pituitary metastases managed with GKRS at a single institution, taken from our prospective registry. All patients had SRS using the Gamma Knife Perfexion or Icon (Elekta), according to our standard institutional protocol. The optic nerves and chiasm were contoured, and the plan was adjusted to restrict dose to the optic apparatus as necessary. The tumor margin doses delivered were 11 Gy, 12 Gy, 14 Gy, 18 Gy (3 sessions of 6 Gy), and 12 Gy at the 50% isodose line.

Results

In this series, all sellar metastases were treated successfully with good radiographic and clinical response. The histology of the tumors included endometrial, gastrointestinal, and lung adenocarcinomas. Typically, histology is taken into consideration when choosing the treatment dose, along with size and location. In these patients, however, the dose used for the sellar metastases was chosen primarily for visual safety. This was typically lower than the dose for brain metastases in other locations.

Conclusion

SRS provides an alternative treatment approach for sellar/suprasellar metastases with excellent local control, symptom improvement and maintenance of systemic therapy as desired. As such, CNS failure is rarely the proximate cause of demise in pituitary metastases provided that endocrinopathies are recognized and managed appropriately.
Literature
6.
go back to reference McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to the pituitary gland. Br J Neurosurg 3(1):71–79CrossRef McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to the pituitary gland. Br J Neurosurg 3(1):71–79CrossRef
8.
go back to reference Schubiger O, Haller D (1992) Metastases to the pituitary–hypothalamic axis. An MR study of 7 symptomatic patients. Neuroradiology 34(2):131–134CrossRef Schubiger O, Haller D (1992) Metastases to the pituitary–hypothalamic axis. An MR study of 7 symptomatic patients. Neuroradiology 34(2):131–134CrossRef
14.
go back to reference Lithgow K, Siqueira I, Senthil L et al (2020) Pituitary metastases: presentation and outcomes from a pituitary center over the last decade. Pituitary 15:242–245 Lithgow K, Siqueira I, Senthil L et al (2020) Pituitary metastases: presentation and outcomes from a pituitary center over the last decade. Pituitary 15:242–245
Metadata
Title
Treatment of sellar metastases with gamma knife radiosurgery in patients with advanced cancer
Authors
Carolina Benjamin
Kimberly Ashayeri
John G. Golfinos
Dimitris G. Placantonakis
Joshua Silverman
Douglas Kondziolka
Publication date
01-12-2020
Publisher
Springer US
Published in
Pituitary / Issue 6/2020
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-020-01074-8

Other articles of this Issue 6/2020

Pituitary 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.